Comparison of Callisphere Drug-Eluting Beads Transarterial Chemoembolization and Conventional Transarterial Chemoembolization for the treatment of Hepatocellular Carcinoma

Yongjun Ren; Caixia Zhao; Yongfu Xiong; Zhongbai Liu; Guo Wu

doi:10.12669/pjms.40.3.8572

Yongjun Ren Affiliated Hospital of North Sichuan Medical College
Caixia Zhao
Yongfu Xiong
Zhongbai Liu
Guo Wu

DOI: https://doi.org/10.12669/pjms.40.3.8572

Keywords: CalliSpheres, Drug-eluting beads transarterial chemoembolization, Conventional transarterial chemoembolization, Hepatocellular carcinoma

Abstract

Objective: To compare the efficacy of CalliSphere drug-eluting beads (DEBs) and conventional (c) transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC).

Methods: We retrospectively reviewed the clinical data of 125 patients with HCC who had received treatment in Affiliated Hospital of North Sichuan Medical College from January 2018 to February 2019. Sixty-one patients underwent DEB-TACE (observation group) and 64 patients underwent cTACE (control group). The clinical efficacies, overall survivals, and incidence of postoperative adverse reactions between the two groups were compared.

Results: The objective response rate in the observation group (85.25%) was higher than that in the control group (70.31%; P<0.05). The disease control in the observation group (96.72%) was higher than that in the control group (85.94%; P<0.05). The median survival time of the observation group (24.85 months) was significantly higher than that in the control group (18.18 months; P<0.05). The incidence of adverse reactions in the observation group (4.92%) was lower than that in the control group (17.19%, P<0.05).

Conclusions: In the treatment of HCC, Callisphere DEB-TACE has better efficacy and longer patient survival with fewer adverse reactions compared to cTACE.

doi: https://doi.org/10.12669/pjms.40.3.8572

How to cite this: Ren Y, Zhao C, Xiong Y, Liu Z, Wu G. Comparison of Callisphere Drug-Eluting Beads Transarterial Chemoembolization and Conventional Transarterial Chemoembolization for the treatment of Hepatocellular Carcinoma. Pak J Med Sci. 2024;40(3):303-307. doi: https://doi.org/10.12669/pjms.40.3.8572

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.